Literature DB >> 7917774

Decreased plasma protein binding of valproate in patients with acute head trauma.

G D Anderson1, B E Gidal, R J Hendryx, A B Awan, N R Temkin, A J Wilensky, H R Winn.   

Abstract

1. One hundred and ten plasma samples were obtained from 50 patients treated with valproate for prophylaxis of post-traumatic head injuries. The samples were selected to include a wide range of albumin concentrations and were assayed for free and total valproate concentrations. Valproate binding parameters were determined from the Scatchard equation for one binding site using reweighted least squares analysis. 2. Plasma albumin concentrations were measured in 130 patients with head trauma. They started to decrease immediately after trauma, reaching a minimum at 5-7 days of approximately 24% of baseline value and did not return to normal until 1 month. 3. The free fraction of valproate varied six to seven-fold as albumin concentration ranged from 1.5 to 4.8 g 100 ml-1 (218-696 mumol l-1). The mean association constant for binding (Ka) was 0.008 mumol l(-1) and the mean number of binding sites (N) was 2.0. There values were similar to those reported for valproate in otherwise healthy patients with epilepsy. 4. Because of saturable protein binding of valproate, hypoalbuminaemia may necessitate the monitoring of free valproate concentrations to avoid toxicity when valproate is used in patients with acute head injury.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7917774      PMCID: PMC1364815          DOI: 10.1111/j.1365-2125.1994.tb04304.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  25 in total

1.  Importance of unbound phenytoin serum levels in head trauma patients.

Authors:  L A Bauer; W A Edwards; E P Dellinger; V A Raisys; C Brennan
Journal:  J Trauma       Date:  1983-12

2.  Protein binding of valproic acid in uremic patients.

Authors:  J Bruni; L H Wang; T C Marbury; C S Lee; B J Wilder
Journal:  Neurology       Date:  1980-05       Impact factor: 9.910

Review 3.  Monitoring of free valproic acid levels?

Authors:  R H Levy
Journal:  Ther Drug Monit       Date:  1980       Impact factor: 3.681

Review 4.  The phenomenon of the acute phase response.

Authors:  I Kushner
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

5.  Valproic acid: in vitro plasma protein binding and interaction with phenytoin.

Authors:  J A Cramer; R H Mattson
Journal:  Ther Drug Monit       Date:  1979       Impact factor: 3.681

6.  Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease.

Authors:  R Gugler; G Mueller
Journal:  Br J Clin Pharmacol       Date:  1978-05       Impact factor: 4.335

7.  Diurnal fluctuations in free and total plasma concentrations of valproic acid at steady state in epileptic patients.

Authors:  R Riva; F Albani; P Cortelli; G Gobbi; E Perucca; A Baruzzi
Journal:  Ther Drug Monit       Date:  1983-06       Impact factor: 3.681

8.  Systemic interaction between valproic acid and free fatty acids in rhesus monkeys.

Authors:  I Johno; M Y Huang; R H Levy
Journal:  Epilepsia       Date:  1982-12       Impact factor: 5.864

9.  Prediction of unbound serum valproic acid concentration by using in vivo binding parameters.

Authors:  Y Kodama; M Kuranari; K Tsutsumi; H Kimoto; I Fujii; M Takeyama
Journal:  Ther Drug Monit       Date:  1992-10       Impact factor: 3.681

10.  Changes in unbound and total valproic acid concentrations after replacement of carbamazepine with oxcarbazepine.

Authors:  D Battino; D Croci; T Granata; G Bernardi; G Monza
Journal:  Ther Drug Monit       Date:  1992-10       Impact factor: 3.681

View more
  5 in total

Review 1.  Pharmacological prophylaxis of post-traumatic epilepsy.

Authors:  A Iudice; L Murri
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

2.  Effect of time, injury, age and ethanol on interpatient variability in valproic acid pharmacokinetics after traumatic brain injury.

Authors:  Gail D Anderson; Nancy R Temkin; Asaad B Awan; H Richard Winn; Richard H Winn
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Increases in metabolism of valproate and excretion of 6beta-hydroxycortisol in patients with traumatic brain injury.

Authors:  G D Anderson; A B Awan; C A Adams; N R Temkin; H R Winn
Journal:  Br J Clin Pharmacol       Date:  1998-02       Impact factor: 4.335

4.  Effect of Traumatic Brain Injury, Erythropoietin, and Anakinra on Hepatic Metabolizing Enzymes and Transporters in an Experimental Rat Model.

Authors:  Gail D Anderson; Todd C Peterson; Cole Vonder Haar; Fred M Farin; Theo K Bammler; James W MacDonald; Eric D Kantor; Michael R Hoane
Journal:  AAPS J       Date:  2015-06-12       Impact factor: 4.009

Review 5.  Pharmacokinetic alterations after severe head injury. Clinical relevance.

Authors:  B A Boucher; S D Hanes
Journal:  Clin Pharmacokinet       Date:  1998-09       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.